SecBot SecBot
PRESS-RELEASE ·Filed Apr 2, 2026

SKYE

Skye Bioscience, Inc.
MIXED
Impact 6/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ◆ Mixed

Watch for topline Part C data in Q4 2026, which will inform Phase 2b dose selection and potential partnership or financing needs. Positive safety and PK data could validate higher dosing and de-risk future development, but lack of funding clarity introduces execution risk.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.6980
T+0 close · Apr 2, 2026 · via day close
Latest settled
−0.67%
T+60 · $0.6933
Vs SPY
−14.83%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 2 $0.6980entry
  2. T+1 · 8mo ago +2.29%α +1.82% · $0.7140
  3. T+5 · 7mo ago +3.15%α −0.47% · $0.7200
  4. T+20 · 7mo ago +25.93%α +16.05% · $0.8790
  5. T+60 · 5mo ago −0.67%α −14.83% · $0.6933
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Skye Bioscience has dosed the first patient in the Part C expansion of its Phase 2a trial for nimacimab, testing higher IV doses (400 mg and 600 mg) to evaluate improved peripheral exposure and safety. The company highlighted strong prior results from combination therapy with semaglutide, showing 22.3% mean weight loss at 52 weeks, and received FDA feedback on its proposed Phase 2b design, though trial progression depends on Part C data and capital availability.

Key Facts

  • First patient dosed in Part C expansion study of nimacimab Phase 2a trial, testing 400 mg IV and 600 mg IV doses.
  • Higher doses correspond to ~700 mg and ~1,000 mg subcutaneous dosing, aiming for greater peripheral tissue exposure.
  • Prior combination data with semaglutide showed 22.3% mean weight loss at 52 weeks, no plateau, and reduced weight regain off-treatment.
  • No drug-related neuropsychiatric adverse events reported in any arm through full study period.
  • Topline data from Part C expected in Q4 2026; Phase 2b trial design contingent on results, regulatory input, and funding.

Financial Impact

No immediate financial impact disclosed; future trial progression dependent on capital availability.

dilutionR&D spendcash runway

Risk Factors

  • Development is contingent on capital availability, risk of delay or halt if financing is not secured.
  • Higher dosing may compromise the CNS-sparing safety profile, undermining nimacimab’s key differentiator.
  • Enrollment in higher-dose cohort depends on safety review, creating binary risk at early stage.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3267226

Track record

16 reports on SKYE

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +82.80% at T+60 after the Aug 14, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago DEFA14A Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
  2. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
  3. Oct 26, 202621d ago PREM14A Bearish 7/10 Entry $1.45 Now $1.07 +26.55% settles Nov 24
  4. Oct 14, 20264w ago SC 13G Neutral 4/10 Entry $1.59 to $1.08 Now $1.07 −33.02% ▼ −32.08% −30.17% vs SPY
  5. Sep 24, 20267w ago Insider Cluster Neutral 3/10 Entry $1.67 to $1.54 Now $1.07 −36.23% ▼ −7.78% −6.31% vs SPY
  6. Sep 24, 20267w ago SC 13D/A Bearish 6/10 Entry $1.67 to $1.54 Now $1.07 +36.23% ▲ +7.78% +6.31% vs SPY
  7. Sep 18, 20268w ago Insider Cluster Bearish 4/10 Entry $1.78 to $1.53 Now $1.07 +40.17% ▲ +14.04% +13.14% vs SPY
  8. Aug 19, 202612w ago DEFA14A Neutral 4/10 Entry $0.2809 to $0.2206 Now $1.07 +279.14% ▼ −21.46% −21.34% vs SPY
  9. Aug 14, 202613w ago 8-K Mixed 7/10 Entry $0.5015 to $0.2487 Now $1.07 +112.36% ▼ −50.40% −48.41% vs SPY
  10. Aug 14, 202613w ago Press Release Bearish 7/10 Entry $0.5015 to $0.2487 Now $1.07 −112.36% ▲ +50.40% +48.41% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 2, 2026